Precursor B-cell lymphoblastic leukemia
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
This is the first spontaneous mouse model of pre-B leukemia to demonstrate inappropriate expression of non-B-cell-specific genes associated with loss of Ebf1, Tcf3 and Runx1 expression.
|
28692033 |
2017 |
Precursor B-cell lymphoblastic leukemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Collectively, our study shows that AML1 gene overexpression characterizes a broader range of leukemic subtypes than previously thought, including various maturation stages of B-cell acute lymphoblastic leukemia and cytogenetic types additional to those involving the AML1 gene.
|
28349830 |
2017 |
Precursor B-cell lymphoblastic leukemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our anecdotal experience suggests that children with B-ALL and RUNX1 amplification might be predisposed to thrombosis.
|
26907657 |
2016 |
Precursor B-cell lymphoblastic leukemia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The most common rearrangement in childhood precursor B-cell acute lymphoblastic leukemia is the t(12;21)(p13;q22) translocation resulting in the ETV6-AML1 fusion gene.
|
27540136 |
2016 |
Precursor B-cell lymphoblastic leukemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Further investigation into the clinical and biological significance of elevated MN1 expression in TEL-AML1(positive) leukemia might provide insight into additional molecular mechanisms contributing to B-ALL and may lead to improved treatment options for patients.
|
26111797 |
2015 |
Precursor B-cell lymphoblastic leukemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
A diagnosis of BCR-ABL1 (p190)-positive and ETV6-RUNX1-positive B-ALL was made, and treatment was initiated according to the AIEOP-BFM-ALL2000 protocol.
|
23491079 |
2013 |
Precursor B-cell lymphoblastic leukemia
|
0.400 |
FusionGene
|
disease |
ORPHANET |
A diagnosis of BCR-ABL1 (p190)-positive and ETV6-RUNX1-positive B-ALL was made, and treatment was initiated according to the AIEOP-BFM-ALL2000 protocol.
|
23491079 |
2013 |
Precursor B-cell lymphoblastic leukemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Results were compared with 494 ETV6-RUNX1-negative B-precursor ALL patients.
|
21869842 |
2012 |
Precursor B-cell lymphoblastic leukemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
These cells correspond to TEL/AML1(pos) ALL (1/4 pediatric B-precursor ALL).
|
18005092 |
2008 |
Precursor B-cell lymphoblastic leukemia
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The degree of anemia was significantly different for three distinct groups of patients compared to the remaining patients (mean hemoglobin; T-cell leukemia: 106 g/L versus 76 g/L (precursor B-cell acute lymphoblastic leukemia); within precursor B-cell ALL: TEL-AML1 positive: 68 g/L versus 79 g/L; BCR-ABL positive: 93 g/L versus 76 g/L; each p<0.05).
|
18815194 |
2008 |
Precursor B-cell lymphoblastic leukemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Persistence of TEL-AML1 fusion gene as minimal residual disease has no additive prognostic value in CD 10 positive B-acute lymphoblastic leukemia: a FISH study.
|
18928518 |
2008 |
Precursor B-cell lymphoblastic leukemia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
ETV6-RUNX1 fusion transcripts were detected in 21 of 92 patients (22.8%): 16 with common ALL, 4 with precursor B-cell ALL, and 1 with T-ALL.
|
17889709 |
2007 |
Precursor B-cell lymphoblastic leukemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
The TEL-AML1 transgenic zebrafish models human pre-B ALL, identifies the molecular pathways associated with leukemia development, and serves as the foundation for subsequent genetic screens to identify modifiers and leukemia therapeutic targets.
|
17015828 |
2006 |
Precursor B-cell lymphoblastic leukemia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Vk-Jk rearrangements were particularly frequent in common-ALL, children between 5-10 years, and TEL-AML1-positive patients.
|
16627258 |
2006 |
Precursor B-cell lymphoblastic leukemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
We show that TEL-AML1 dramatically alters differentiation of HPCs in vitro, preferentially promoting B-lymphocyte development, enhancing self-renewal of B-cell precursors, and leading to the establishment of long-term growth factor-dependent pre-B-cell lines.
|
14726384 |
2004 |
Precursor B-cell lymphoblastic leukemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Thus, TEL/AML1 protein acts as a transcriptional repressor of MDR-1 gene expression, and although TEL/AML1 has been implicated in leukemogenesis, its effects on the MDR-1 gene may contribute to the excellent prognosis of TEL/AML1-positive ALL with current therapy.
|
15235109 |
2004 |
Precursor B-cell lymphoblastic leukemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
A fluorescence in situ hybridization study of TEL-AML1 fusion gene in B-cell acute lymphoblastic leukemia (1984-2001).
|
12850377 |
2003 |
Precursor B-cell lymphoblastic leukemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
The IgH, TCR and TEL-AML1 markers can be used as targets by real-time PCR under the same cycling profile, allowing quantitation of MRD in more 95% of patients with pre-B ALL.
|
12571459 |
2003 |
Precursor B-cell lymphoblastic leukemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
We propose, in some cases, that the TEL-AML1 translocation occurs in a stem or B progenitor cell, and that recurrent TEL-AML1-positive pre-B ALL represents a de novo-transformed population that retains the same diagnostic initiating event.
|
12526921 |
2003 |
Precursor B-cell lymphoblastic leukemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Therefore, we conclude that the TEL-AML1 RQ-PCR can, in principle, replace Ig/TCR RQ-PCR in B-precursor ALL with t(12;21).
|
11841400 |
2002 |
Precursor B-cell lymphoblastic leukemia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Two of 9 TEL-AML1 mice developed ALL (one T-lineage ALL and one B-precursor ALL), whereas 0 of 20 control mice developed leukemia.
|
12124316 |
2002 |
Precursor B-cell lymphoblastic leukemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
However, this group was not representative as it included a high number of relapsed patients compared with the normal incidence in B-precursor ALL [54 in continuous complete remission (CCR) and 36 relapsed patients] and only a slightly better prognosis for TEL/AML1-positive patients was found (not significant) (four relapses in 17 TEL/AML1-positive patients vs. 32 relapses in 73 TEL/AML1-negative patients).
|
11167743 |
2000 |
Precursor B-cell lymphoblastic leukemia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The TEL-AML1 fusion which results from the t(12;21) rearrangement in childhood B-precursor acute lymphoblastic leukaemia (B-precursor ALL) is often accompanied by loss of the untranslocated TEL allele.
|
11426627 |
2000 |
Precursor B-cell lymphoblastic leukemia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Surface antigen phenotype can predict TEL-AML1 rearrangement in childhood B-precursor ALL: a Pediatric Oncology Group study.
|
9823952 |
1998 |
Precursor B-cell lymphoblastic leukemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
The 63 cases positive for the TEL/AML1 chimeric products ranged in age between 1 and 12 years, and all but one showed CD10 and pre-B immunophenotype.
|
9226156 |
1997 |